

PRODUCT MONOGRAPH  
INCLUDING PATIENT MEDICATION INFORMATION

**MOTRIN® LIQUID GELS 200 mg**

Ibuprofen Capsules (free acid and potassium salt)

Capsule, 200 mg, Oral

**MOTRIN® LIQUID GELS 400 mg**

Ibuprofen Capsules (free acid and potassium salt)

Capsule, 400 mg, Oral

Non-Steroidal Anti-inflammatory Drug

Analgesic/Antipyretic

McNeil Consumer Healthcare  
Division of Johnson & Johnson Inc.  
88 McNabb Street  
Markham, Canada  
L3R 5L2

Date of Initial Authorization:  
[OCT 31,2007]

Date of Revision:  
April 5, 2023

Submission Control Number: 265373

## RECENT MAJOR LABEL CHANGES

3 SERIOUS WARNINGS AND PRECAUTIONS BOX		04/2023
7 WARNINGS AND PRECAUTIONS	Monitoring and Laboratory Tests	04/2023
7 WARNINGS AND PRECAUTIONS	7.1.1 Pregnant Women	04/2023

## TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

<b>RECENT MAJOR LABEL CHANGES</b> .....	<b>2</b>
<b>TABLE OF CONTENTS</b> .....	<b>2</b>
<b>PART I: HEALTH PROFESSIONAL INFORMATION</b> .....	<b>4</b>
<b>1 INDICATIONS</b> .....	<b>4</b>
1.1 Pediatrics .....	4
1.2 Geriatrics .....	4
<b>2 CONTRAINDICATIONS</b> .....	<b>4</b>
<b>3 SERIOUS WARNINGS AND PRECAUTIONS BOX</b> .....	<b>6</b>
<b>4 DOSAGE AND ADMINISTRATION</b> .....	<b>6</b>
4.1 Dosing Considerations .....	6
4.2 Recommended Dose and Dosage Adjustment .....	6
4.5 Missed Dose .....	7
<b>5 OVERDOSAGE</b> .....	<b>7</b>
<b>6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING</b> .....	<b>8</b>
<b>7 WARNINGS AND PRECAUTIONS</b> .....	<b>9</b>
7.1 Special Populations .....	15
7.1.1 Pregnant Women .....	15
7.1.2 Breast-feeding .....	17
7.1.3 Pediatrics .....	17
7.1.4 Geriatrics .....	17
<b>8 ADVERSE REACTIONS</b> .....	<b>17</b>

8.1	Adverse Reaction Overview.....	17
8.2	Clinical Trial Adverse Reactions .....	18
8.4	Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data .....	18
8.5	Post-Market Adverse Reactions.....	18
<b>9</b>	<b>DRUG INTERACTIONS .....</b>	<b>22</b>
9.1	Serious Drug Interactions .....	22
9.2	Drug Interactions Overview.....	22
9.4	Drug-Drug Interactions .....	23
9.5	Drug-Food Interactions .....	25
9.6	Drug-Herb Interactions .....	26
9.7	Drug-Laboratory Test Interactions .....	26
<b>10</b>	<b>CLINICAL PHARMACOLOGY .....</b>	<b>26</b>
10.1	Mechanism of Action.....	26
10.2	Pharmacodynamics .....	26
10.3	Pharmacokinetics .....	27
<b>11</b>	<b>STORAGE, STABILITY AND DISPOSAL .....</b>	<b>29</b>
<b>12</b>	<b>SPECIAL HANDLING INSTRUCTIONS.....</b>	<b>29</b>
<b>PART II: SCIENTIFIC INFORMATION .....</b>		<b>30</b>
<b>13</b>	<b>PHARMACEUTICAL INFORMATION.....</b>	<b>30</b>
<b>14</b>	<b>CLINICAL TRIALS .....</b>	<b>30</b>
14.1	Trial Design and Study Demographics .....	30
14.2	Study Results .....	31
14.3	Comparative Bioavailability Studies.....	33
<b>15</b>	<b>MICROBIOLOGY .....</b>	<b>34</b>
<b>16</b>	<b>NON-CLINICAL TOXICOLOGY .....</b>	<b>34</b>
<b>17</b>	<b>SUPPORTING PRODUCT MONOGRAPHS.....</b>	<b>36</b>
<b>PATIENT MEDICATION INFORMATION.....</b>		<b>37</b>
<b>PATIENT MEDICATION INFORMATION.....</b>		<b>44</b>

## **PART I: HEALTH PROFESSIONAL INFORMATION**

### **1 INDICATIONS**

MOTRIN® Liquid Gels 200 mg/ MOTRIN® Liquid Gels 400 mg (Ibuprofen) are indicated for:

- headache pain including tension headache;
- mild to moderate migraine headaches including associated symptoms of nausea, and sensitivity to light and sound;
- relief of minor aches and pains in muscles, bones and joints, body pain, backache, muscle sprains and strains;
- pain from inflammation associated with conditions including:
  - arthritis
  - physical or athletic overexertion (e.g. sprains or strains);
- menstrual pain (dysmenorrhea);
- toothache (dental pain);
- aches and pains due to the common cold and flu;
- reduction of fever.

#### **1.1 Pediatrics**

Pediatrics (< 12 years of age): MOTRIN® Liquid Gels 200 mg/ MOTRIN® Liquid Gels 400 mg (Ibuprofen) is not indicated for children <12 years of age. Children's MOTRIN® formulations are available to treat children under 12 years of age (*see Children's MOTRIN® Product Monograph*).

#### **1.2 Geriatrics**

Geriatrics (> 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness and a brief discussion can be found in the appropriate sections (See 7 WARNINGS AND PRECAUTIONS). Therefore, the use of MOTRIN® Liquid Gels 200 mg / MOTRIN® Liquid Gels 400 mg (Ibuprofen) in this population is not recommended.

### **2 CONTRAINDICATIONS**

- Active peptic ulcer, a history of recurrent ulceration or active inflammatory disease of the gastrointestinal system.
- Known or suspected hypersensitivity to the drug or other non-steroidal anti-inflammatory drugs. Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see 6 Dosage Forms, Strengths, Composition and Packaging section of the product monograph. The potential for cross-

reactivity between different NSAIDs must be kept in mind.

- MOTRIN® Liquid Gels 200 mg/ MOTRIN® Liquid Gels 400 mg should not be used in patients with the complete or partial syndrome of nasal polyps, or in whom asthma, anaphylaxis, urticarial/angioedema, rhinitis or other allergic manifestations are precipitated by ASA or other nonsteroidal anti-inflammatory agents. Fatal anaphylactoid reactions have occurred in such individuals. As well, individuals with the above medical problems are at risk of a severe reaction even if they have taken NSAIDs in the past without any adverse effects.
- Significant hepatic impairment or active liver disease.
- Severely impaired or deteriorating renal function (creatinine clearance <30 mL/min). Individuals with lesser degrees of renal impairment are at risk of deterioration of their renal function when prescribed NSAIDs and must be monitored.
- Ibuprofen is not recommended for use with other NSAIDs because of the absence of any evidence demonstrating synergistic benefits and the potential for additive side effects (*See 9 DRUG INTERACTIONS*).
- Children with kidney disease and children who have suffered significant fluid loss due to vomiting, diarrhea or lack of fluid intake, should not be given ibuprofen.
- The third trimester of pregnancy, because of risk of premature closure of the ductus arteriosus, and prolonged parturition.
- Ibuprofen is contraindicated in patients with systemic lupus erythematosus, as an anaphylaxis-like reaction with fever may occur, particularly when ibuprofen has been administered previously.
- Known hyperkalemia (*see 7 WARNINGS AND PRECAUTIONS, Fluid and Electrolyte Balance*)
- Right before or after heart surgery
- Children and adolescents (*see 1 INDICATIONS*).

### 3 SERIOUS WARNINGS AND PRECAUTIONS BOX

#### Serious Warnings and Precautions

- Use with caution in patients with heart failure, hypertension or other conditions predisposing to fluid retention (*See 7 WARNINGS AND PRECAUTIONS, Cardiovascular and Fluid and Electrolyte Balance; and 9 DRUG INTERACTIONS, Antihypertensives*).
- Caution in patients prone to gastrointestinal tract irritation, including those with a history of peptic ulcer (*See 7 WARNINGS AND PRECAUTIONS, Gastrointestinal and 9 DRUG INTERACTIONS, Coumarin-type anticoagulants*).
- Patients at greatest risk of renal toxicity are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and the elderly (*See 7 WARNINGS AND PRECAUTIONS, Renal*).
- If urinary symptoms, hematuria and cystitis occur, the drug should be stopped immediately (*See 7 WARNINGS AND PRECAUTIONS, Genitourinary*).
- Risk in Pregnancy: Caution should be exercised in prescribing MOTRIN® Liquid Gels 200 mg/ MOTRIN® Liquid Gels 400 mg, if trying to conceive, during the first and second trimesters of pregnancy, or nursing. Use of NSAIDs at approximately 20 weeks of gestation or later may cause oligohydramnios, and renal dysfunction including renal failure (*see 7 WARNINGS AND PRECAUTIONS*). MOTRIN® Liquid Gels 200 mg/ MOTRIN® Liquid Gels 400 mg is contraindicated for use during the third trimester because of risk of premature closure of the ductus arteriosus and uterine inertia (prolonged parturition) (*see 2 CONTRAINDICATIONS*).

### 4 DOSAGE AND ADMINISTRATION

#### 4.1 Dosing Considerations

- Do not take for fever for more than 3 days or for pain for more than 5 days unless directed by a physician.

The safety issues to consider when developing a dosage regimen of MOTRIN® Liquid Gels 200 mg/ MOTRIN® Liquid Gels 400 mg for individual patients are applicable to:

- Elderly patients older than 65 years who are frail or debilitated and consideration should be given to a starting dose lower than the one usually recommended (*See 7 WARNINGS AND PRECAUTIONS, Geriatrics*).

#### 4.2 Recommended Dose and Dosage Adjustment

MOTRIN® Liquid Gels 200 mg:

- Adults and Children over 12: Take 1 (every 4 hours) or 2 (every 6-8 hours) capsules as needed. Do not exceed six 200 mg capsules in 24 hours, unless directed by a physician.

MOTRIN® Liquid Gels 400 mg

- Adults and Children over 12: Take 1 400 mg capsule every 6-8 hours as needed. Do not exceed 3 400 mg capsules in 24 hours, unless directed by a physician.

The administration of ibuprofen with food or milk is recommended since occasional and mild heartburn, upset stomach or stomach pain may occur with its use.

#### **4.5 Missed Dose**

Take the missed dose as soon as you remember. If it is almost time for your next dose, wait until then to take your medicine and skip your missed dose. Do not take two doses at the same time.

## **5 OVERDOSAGE**

### **Symptoms of Overdose**

The toxicity of ibuprofen overdose is dependent upon the amount of drug ingested and the time elapsed since ingestion; individual responses may vary, thus making it necessary to evaluate each case separately. Although uncommon, serious toxicity and death have been reported with ibuprofen overdose. The most frequently reported symptoms of ibuprofen overdose include abdominal pain, nausea, vomiting, lethargy and drowsiness. Other CNS symptoms include headache, tinnitus, CNS depression and seizures. Metabolic acidosis, coma, renal tubular acidosis, acute renal failure and apnoea (primarily in very young pediatric patients) may rarely occur. Cardiovascular toxicity, including hypotension, bradycardia, tachycardia and atrial fibrillation, also have been reported.

### **Treatment of Overdose**

In cases of acute overdose, the stomach should be emptied through induction of emesis (in alert patients only) or gastric lavage. Emesis is most effective if initiated within 30 minutes of ingestion. Orally administered activated charcoal may help in reducing the absorption of ibuprofen when given less than 2 hours following ingestion. There is some evidence that repeated administration of activated charcoal may bind the medication that has diffused from the circulation. Inducing diuresis may be helpful. The treatment of acute overdose is primarily supportive. Management of hypotension, acidosis and gastrointestinal bleeding may be necessary.

**In pediatric patients**, the estimated amount of ibuprofen ingested per body weight may be helpful to predict the potential for development of toxicity although each case must be evaluated. Ingestion of less than 100 mg/kg is unlikely to produce toxicity. Pediatric patients ingesting 100 to 200 mg/kg may be managed with induced emesis and a minimal observation time of at least four hours. Pediatric patients ingesting 200 to 400 mg/kg of ibuprofen should have immediate gastric emptying and at least four hours observation. Pediatric patients ingesting greater than 400 mg/kg require immediate medical referral, careful observation and appropriate supportive therapy. Induced emesis is not recommended in overdoses greater than 400 mg/kg because of the risk for convulsions and the potential for aspiration of gastric contents.

**In adult patients**, the dose reportedly ingested does not appear to be predictive of toxicity. The need for referral and follow-up must be judged by the circumstances at the time of the overdose ingestion. Symptomatic adults should be carefully evaluated, observed and supported.

### Examples of Ibuprofen Overdose

A 41-year-old man with multiple medical problems, including long-term renal insufficiency, developed near-fatal acute renal failure after ingestion of a massive dose (36 g) of ibuprofen. He required dialysis for several months, at which point his renal function improved.

In children, ibuprofen overdoses less than 100 mg/kg are unlikely to produce toxicity. In adults, the dose of ibuprofen reportedly ingested does not appear to be predictive of toxicity.

With electrolyte replacement and other intensive measures, a 21-month-old child recovered within 5 days after accidental ingestion of 8 g of ibuprofen. A 2-year-old child who ingested approximately 8 g of ibuprofen was treated with activated charcoal, developed metabolic acidosis and acute renal insufficiency, and recovered within 72 hours. A 6-year-old child became comatose after ingesting 6 g of ibuprofen. He was treated with gastric lavage, charcoal, and various supportive measures and recovered within 24 hours.

For management of a suspected drug overdose, contact your regional poison control centre.

## 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

**Table – Dosage Forms, Strengths, Composition and Packaging**

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
Oral	Capsule / 200 mg	Gelatin, pharmaceutical ink, polyethylene glycol, potassium hydroxide, propylene glycol, purified water and sorbitol
Oral	Capsule / 400 mg	Gelatin, pharmaceutical ink, polyethylene glycol, potassium hydroxide, propylene glycol, purified water, and sorbitol

**MOTRIN® Liquid Gels 200 mg:** A clear, oblong softgel capsule printed with the “M 200” logo in black ink.



MOTRIN® Liquid Gels 200 mg are available in bottles of 16's, 72's and 90's.

MOTRIN® Liquid Gels 400 mg: A clear, colourless pale yellow solution in a clear oval soft gelatin shell printed with the "M 400" logo in black ink.

MOTRIN® Liquid Gels 400 mg are available in bottles of 30's and 60's.

## **7 WARNINGS AND PRECAUTIONS**

*Please see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX.*

### **General**

In common with other anti-inflammatory drugs, ibuprofen may mask the usual signs of infection.

MOTRIN® Liquid Gels 200 mg/ MOTRIN® Liquid Gels 400 mg is NOT recommended for use with other NSAIDs because of the absence of any evidence demonstrating synergistic benefits and the potential for additive adverse reactions. (*See 9 DRUG INTERACTIONS– Drug-Drug Interactions – Acetylsalicylic acid (ASA) or other NSAIDs*)

### **Carcinogenesis and Mutagenesis**

Not applicable.

### **Cardiovascular**

Use of ibuprofen may precipitate congestive heart failure in patients with marginal cardiac function, elevated blood pressure and palpitations.

Long term continuous use may increase the risk of heart attack or stroke.

### **Dependence/Tolerance**

Not applicable.

### **Ear/Nose/Throat**

Patients with complete or partial syndrome of nasal polyps should not use ibuprofen (*See 2 CONTRAINDICATIONS*).

## **Endocrine and Metabolism**

Not applicable.

## **Fluid and Electrolyte Balance**

Fluid retention and oedema have been observed in patients treated with ibuprofen. Therefore, as with many other nonsteroidal anti-inflammatory drugs, the possibility of precipitating congestive heart failure in elderly patients or those with compromised cardiac function should be borne in mind. MOTRIN® Liquid Gels 200 mg/ MOTRIN® Liquid Gels 400 mg (Ibuprofen) should be used with caution in patients with heart failure, hypertension or other conditions predisposing to fluid retention.

With nonsteroidal anti-inflammatory treatment there is a potential risk of hyperkalemia, particularly in patients with conditions such as diabetes mellitus or renal failure; elderly patients; or in patients receiving concomitant therapy with B-adrenergic blockers, angiotensin converting enzyme inhibitors or some diuretics. Serum electrolytes should be monitored periodically during long-term therapy, especially in those patients who are at risk.

## **Gastrointestinal**

Serious GI toxicity, such as peptic ulceration, perforation and gastrointestinal bleeding, sometimes severe and occasionally fatal, can occur at any time, with or without symptoms in patients treated with NSAIDs including ibuprofen.

Minor upper GI problems, such as dyspepsia, are common, usually developing early in therapy. Physicians should remain alert for ulceration and bleeding in patients treated with non-steroidal anti-inflammatory drugs, even in the absence of previous GI tract symptoms.

In patients observed in clinical trials of such agents, symptomatic upper GI ulcers, gross bleeding, or perforation appear to occur in approximately 1% of patients treated for 3-6 months and in about 2-4% of patients treated for one year. The risk continues beyond one year and possibly increases. The incidence of these complications increases with increasing dose.

MOTRIN® Liquid Gels 200 mg/ MOTRIN® Liquid Gels 400 mg should be given under close medical supervision to patients prone to gastrointestinal tract irritation, particularly those with a history of peptic ulcer, diverticulosis or other inflammatory disease of the gastrointestinal tract such as ulcerative colitis and Crohn's disease. In these cases the physician must weigh the benefits of treatment against the possible hazards.

Physicians should inform patients about the signs and/or symptoms of serious GI toxicity and instruct them to contact a physician immediately if they experience persistent dyspepsia or other symptoms or signs suggestive of gastrointestinal ulceration or bleeding. Because serious GI tract ulceration and bleeding can occur without warning symptoms, physicians should

follow chronically treated patients by checking their haemoglobin periodically and by being vigilant for the signs and symptoms of ulceration and bleeding and should inform the patients of the importance of this follow-up.

If ulceration is suspected or confirmed, or if GI bleeding occurs, IBUPROFEN CAPSULES, 200 mg/IBUPROFEN CAPSULES, 400 mg should be discontinued immediately, appropriate treatment instituted and the patient monitored closely.

No studies, to date, have identified any group of patients not at risk of developing ulceration and bleeding. The major risk factors are a prior history of serious GI events and increasing age. Possible risk factors include other factors such as *Helicobacter pylori* infection, excess alcohol intake, smoking, female gender and concomitant oral steroid and anticoagulant, anti-coagulants, anti-platelet agents (including ASA) or selective serotonin reuptake inhibitors (SSRI's) have been associated with increased risk. Studies to date show that all NSAIDs can cause GI tract adverse events. Although existing data does not clearly identify differences in risk between various NSAIDs, this may be shown in the future.

There is no definitive evidence that the concomitant administration of histamine H2-receptor antagonists and/or antacids will either prevent the occurrence of gastrointestinal side effects or allow the continuation of MOTRIN® Liquid Gels 200 mg/ MOTRIN® Liquid Gels 400 mg therapy when and if these adverse reactions appear.

### **Genitourinary**

Some NSAIDs are known to cause persistent urinary symptoms (bladder pain, dysuria, urinary frequency), hematuria or cystitis. The onset of these symptoms may occur at any time after the initiation of therapy with an NSAID. Some cases have become severe on continued treatment. Should urinary symptoms occur, treatment with MOTRIN® Liquid Gels 200 mg/ MOTRIN® Liquid Gels 400 mg must be stopped immediately to obtain recovery. This should be done before any urological investigations or treatments are carried out.

### **Hematologic**

Drugs inhibiting prostaglandin biosynthesis do interfere with platelet function to varying degrees; therefore, patients who may be adversely affected by such an action such as those on anti-coagulants or suffering from haemophilia or platelet disorder should be carefully observed when ibuprofen is administered. Numerous studies have shown that the concomitant use of NSAIDs and anti-coagulants increases the risk of bleeding. Concurrent therapy with warfarin requires close monitoring of the international normalized ratio (INR). Even with therapeutic INR monitoring, increased bleeding may occur. (See 9 DRUG INTERACTIONS)

Blood dyscrasias (such as neutropenia, leukopenia, thrombocytopenia, aplastic anaemia and

agranulocytosis) associated with the use of non-steroidal anti-inflammatory drugs are rare but could occur with severe consequences.

### **Hepatic/Biliary/Pancreatic**

As with other nonsteroidal anti-inflammatory drugs, borderline elevations of one or more liver function tests may occur in up to 15% of patients. These abnormalities may progress, may remain essentially unchanged, or may be transient with continued therapy.

A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of more severe hepatic reaction while on therapy with this drug. Severe hepatic reactions including jaundice and cases of fatal hepatitis have been reported with nonsteroidal anti-inflammatory drugs. Very rarely, ibuprofen has been reported to cause vanishing bile duct syndrome. Patients should seek medical advice if they develop sudden onset abdominal pain or chronic abdominal pain associated with loss of appetite and/or jaundice and/or new onset itching.

Although such reactions are rare, if abnormal liver tests persist or worsen, if clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g. eosinophilia, rash, etc.), this drug should be discontinued.

During long-term therapy, liver function tests should be monitored periodically. If there is a need to prescribe this drug in the presence of impaired liver function, it must be done under strict observation.

The frequency of acute liver injury among 625,307 people who received NSAIDs in England and Wales between 1987 and 1991, was examined. There were 311,716 patients who were prescribed ibuprofen. The incidence of acute liver injury among ibuprofen users was 1.6/100,000; this was the lowest incidence among the 8 NSAIDs studied and was significantly lower than the incidence among users of ketoprofen, piroxicam, fenbrufen, or sulindac. For NSAID users as a group, the only factors that had an independent effect on the occurrence of acute liver injury were the simultaneous use of hepatotoxic medication or the presence of rheumatoid arthritis. Based on these data, the short-term use of ibuprofen as an analgesic/antipyretic should not be of concern regarding the development of liver disease.

### **Immune**

Patients with complete or partial syndrome of nasal polyps, rhinitis or other allergic manifestations should not use ibuprofen or other anti-inflammatory agents. Fatal anaphylactoid reactions have occurred in such individuals even if they have taken NSAIDs in the past without any adverse effects (See 2 *CONTRAINDICATIONS*).

In occasional cases, with some NSAIDs, the symptoms of aseptic meningitis (stiff neck, severe headaches, nausea and vomiting, fever or clouding of consciousness) have been observed.

Patients with autoimmune disorders (systemic lupus erythematosus, mixed connective tissue diseases, etc.) seem to be pre-disposed. Therefore, in such patients, the physician must be vigilant to the development of this complication.

### **Monitoring and Laboratory Tests**

For Monitoring and Laboratory Tests related to the use of ibuprofen see 7 *WARNINGS AND PRECAUTIONS, Fluid and Electrolyte Balance, Gastrointestinal, Hematologic, Hepatic, Renal and Special populations: Geriatrics.*

**Pregnancy:** If MOTRIN® Liquid Gels 200 mg/ MOTRIN® Liquid Gels 400 mg is administered in the middle (approximately 20 weeks) to the end of the second trimester, it is recommended that pregnant women on MOTRIN® Liquid Gels 200 mg/ MOTRIN® Liquid Gels 400 mg be closely monitored for amniotic fluid volume since MOTRIN® Liquid Gels 200 mg/ MOTRIN® Liquid Gels 400 mg may result in reduction of amniotic fluid volume and even oligohydramnios (see 7.1 Special Populations). MOTRIN® Liquid Gels 200 mg/ MOTRIN® Liquid Gels 400 mg is CONTRAINDICATED for use in the third trimester of pregnancy.

### **Neurologic**

Some patients may experience drowsiness, dizziness, vertigo, insomnia or depression with the use of ibuprofen. If patients experience these side effects, they should exercise caution in carrying out activities that require alertness.

### **Ophthalmologic**

Blurred and/or diminished vision has been reported with the use of ibuprofen and other non-steroidal anti-inflammatory drugs. If such symptoms develop, this drug should be discontinued and an ophthalmologic examination performed; ophthalmic examination should be carried out at periodic intervals in any patient receiving this drug for an extended period of time.

### **Peri-Operative Considerations**

In general, NSAIDs should be discontinued prior to surgeries to decrease the risk of post-operative bleeding (*See 2 CONTRAINDICATIONS*).

### **Psychiatric**

See 7 *Warnings and Precautions, Neurologic.*

## Renal

Long term administration of nonsteroidal anti-inflammatory drugs to animals has resulted in renal papillary necrosis and other abnormal renal pathology. In humans, there have been reports of acute interstitial nephritis with hematuria, proteinuria, and occasionally nephrotic syndrome.

A second form of renal toxicity has been seen in patients with prerenal conditions leading to the reduction in renal blood flow or blood volume, where the renal prostaglandins have a supportive role in the maintenance of renal perfusion. In these patients, administration of a nonsteroidal anti-inflammatory drug may cause a dose dependent reduction in prostaglandin formation and may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, and the elderly. Discontinuation of nonsteroidal anti-inflammatory therapy is usually followed by recovery to the pre-treatment state.

Ibuprofen and its metabolites are eliminated primarily by the kidneys; therefore the drug should be used with great caution in patients with impaired renal function. Severely impaired or deteriorating renal function (creatinine clearance <30 mL/min) are at risk. Individuals with lesser degrees of renal impairment are at risk of deterioration of their renal function when prescribed NSAIDs. In these cases, lower doses of ibuprofen should be considered and patients carefully monitored.

During long-term therapy kidney function should be monitored periodically.

## Respiratory

ASA-induced asthma is an uncommon but very important indication of ASA and NSAID sensitivity. It occurs more frequently in patients with asthma who have nasal polyps. Patients with asthma or other allergic manifestations should not use ibuprofen or other nonsteroidal anti-inflammatory agents. Fatal anaphylactoid reactions have occurred in such individuals even if they have taken NSAIDs in the past without any adverse effects (See 2 *CONTRAINDICATIONS*).

## Sensitivity/Resistance

Patients sensitive to any one of the nonsteroidal anti-inflammatory drugs may be sensitive to any of the other NSAIDs also.

## Skin

Ibuprofen may cause a severe allergic reaction, especially in patients allergic to acetylsalicylic acid. Symptoms may include hives, facial swelling, asthma (wheezing), shock, skin reddening, rash or blisters with or without pyrexia or erythema. If any of these symptoms occur, patients should stop use and seek medical help right away.

Serious skin reactions such as exfoliative dermatitis, Erythema Multiforme (EM), Stevens – Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and Acute Generalized Exanthematous Pustulosis (AGEP) have been reported very rarely in patients receiving ibuprofen. Because the rate of these reactions is low, they have usually been noted during post-marketing surveillance in patients taking other medications also associated with the potential development of these serious skin reactions. Thus, causality is NOT clear. These reactions are potentially life threatening but may be reversible if the causative agent is discontinued and appropriate treatment instituted. Patients should be advised that if they experience a skin rash they should discontinue their NSAID and contact their physician for assessment and advice, including which additional therapies to discontinue. NSAIDs should be discontinued at the first appearance of rash or any other sign of hypersensitivity.

Some people may become more sensitive to sunlight than they are normally. Brief exposure to sunlight or sunlamps may cause sunburn, blisters on the skin, skin rash, redness, itching or discoloration or vision changes.

## **7.1 Special Populations**

### **7.1.1 Pregnant Women**

**Ibuprofen is CONTRAINDICATED for use during the third trimester of pregnancy because of risk of premature closure of the ductus arteriosus and the potential to prolong parturition (see 2 CONTRAINDICATIONS).**

**Caution should be exercised in prescribing MOTRIN® to women who are trying to conceive, during the first and second trimesters of pregnancy, or if breastfeeding (see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX).**

Because of the known effects of NSAIDs on the fetal cardiovascular system, use of ibuprofen during late pregnancy should be avoided. As with other drugs known to inhibit prostaglandin synthesis, an increased incidence of dystocia and delayed parturition occurred in rats. Administration of ibuprofen is not recommended during pregnancy.

#### **Oligohydramnios/Neonatal Renal Impairment:**

Use of NSAIDs, including MOTRIN® Liquid Gels 200 mg/ MOTRIN® Liquid Gels 400 mg, at approximately 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some more severe cases, neonatal respiratory, musculoskeletal and renal problems.

Published studies and post-marketing reports describe maternal NSAID use at approximately 20 weeks gestation or later in pregnancy associated with fetal renal

dysfunction leading to oligohydramnios, and in some cases, neonatal renal impairment, or failure. NSAIDs were shown to cause significant reduction in fetal urine production prior to reduction of amniotic fluid volume. There have also been a limited number of case reports of maternal NSAID use and neonatal renal dysfunction without oligohydramnios, some of which were irreversible, even after treatment discontinuation.

These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation. In some post-marketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required.

If, after careful consideration of alternative treatment options for pain management, NSAID treatment is necessary anywhere from the middle (onset approximately 20 weeks) to the end of the second trimester of pregnancy, it is recommended that the use be limited to the lowest effective dose and shortest duration possible.

Consider ultrasound monitoring of fetal well-being, including of amniotic fluid volume assessment if MOTRIN® Liquid Gels 200 mg/ MOTRIN® Liquid Gels 400 mg treatment extends beyond 48 hours. It is recommended that NSAIDs treatment be discontinued if oligohydramnios occurs, followed by appropriate medical follow up.

Inform pregnant women not to use MOTRIN® Liquid Gels 200 mg/ MOTRIN® Liquid Gels 400 mg and other NSAIDs from the third trimester of pregnancy because of the risk of the premature closing of the fetal ductus arteriosus (*see 2 CONTRAINDICATIONS*). If treatment with MOTRIN® Liquid Gels 200 mg/ MOTRIN® Liquid Gels 400 mg is needed for a pregnant woman anywhere from the middle (onset approximately 20 weeks gestation to the end of the second trimester of pregnancy), advise her that she may need to be monitored for oligohydramnios, if treatment continues for longer than 48 hours.

Inhibition of prostaglandin synthesis may adversely affect pregnancy and/or embryo-fetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation after use of a prostaglandin synthesis inhibitor in early pregnancy.



In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-fetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period.

### **7.1.2 Breast-feeding**

**Nursing Women:** The high protein binding and lower pH of breast milk versus plasma tend to inhibit the excretion of ibuprofen into breast milk. One study showed an ibuprofen concentration of 13 ng/mL 30 minutes after ingesting 400 mg. The milk: plasma ratio was 1:126. This translates to an infant exposure of 0.0008% of the maternal dose. It is not known to what extent, if any, ibuprofen crosses the human placenta.

### **7.1.3 Pediatrics**

The safety and efficacy of ibuprofen in children <12 years of age have not been demonstrated for the products mentioned in this monograph.

### **7.1.4 Geriatrics**

Patients older than 65 years and frail or debilitated patients are most susceptible to a variety of adverse reactions from nonsteroidal anti-inflammatory drugs (NSAIDs): the incidence of these adverse reactions increases with dose and duration of treatment. In addition, these patients are less tolerant to ulceration and bleeding. The chance of stomach bleeding is higher if you are age 60 or older, have had stomach ulcers or bleeding problems, take a blood thinner or steroid drug, take with other drugs containing an NSAID like acetylsalicylic acid (ASA), ibuprofen, naproxen, or prescription anti-inflammatory drugs, have 3 or more alcoholic drinks every day while using this product. Most reports of fatal GI events are in this population. Older patients are also at risk of lower oesophageal ulceration and bleeding.

For such patients, consideration should be given to a starting dose lower than the one usually recommended, with individual adjustment when necessary and under close supervision.

## **8 ADVERSE REACTIONS**

### **8.1 Adverse Reaction Overview**

Experience reported with prescription use of ibuprofen has included the adverse reactions listed in this section. Note: Reactions listed under Causal Relationship Unknown are those

where a causal relationship could not be established; however, in these rarely reported events, the possibility of a relationship to ibuprofen also cannot be excluded. The adverse reactions most frequently seen with ibuprofen therapy involve the gastrointestinal system.

## **8.2 Clinical Trial Adverse Reactions**

Not available.

## **8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data**

**Gastrointestinal:** The generally modest elevations of serum transaminase activity that has been observed are usually without clinical sequelae but severe, potentially fatal toxic hepatitis can occur.

**Renal:** Renal blood flow glomerular filtration rate decreased in patients with mild impairment of renal functions who took 1200 mg/day of ibuprofen for one week. Renal papillary necrosis has been reported. A number of factors appear to increase the risk of renal toxicity.

## **8.5 Post-Market Adverse Reactions (Prescription Experience)**

The following adverse reactions have been noted in patients treated with prescription doses ( $\geq 1200$  mg/day).

Note: Reactions listed below under Causal Relationship Unknown are those which occurred under circumstances where a causal relationship could not be established. However, in these rarely reported events, the possibility of a relationship to ibuprofen cannot be excluded.

### **Gastrointestinal**

The adverse reactions most frequently seen with prescribed ibuprofen therapy involve the gastrointestinal system.

Incidence 3 to 9%: nausea, epigastric pain, heartburn

Incidence 1 to 3%: diarrhea, abdominal distress, nausea and vomiting, indigestion, constipation, abdominal cramps or pain, fullness of the gastrointestinal tract (bloating or flatulence).

Incidence less than 1%: gastric or duodenal ulcer with bleeding and/or perforation, gastrointestinal haemorrhage, melena, hepatitis, jaundice, abnormal liver function (SGOT, serum bilirubin and alkaline phosphatase), pancreatitis, oral discomfort (local burning, sensation, irritation).

## **Allergic**

Incidence less than 1%: anaphylaxis (see CONTRAINDICATIONS).

Causal relationship unknown: fever, serum sickness, lupus erythematosus.

## **Central Nervous System**

Incidence 3 to 9%: dizziness

Incidence 1 to 3%: headache, nervousness

Incidence less than 1%: depression, insomnia

Causal relationship unknown: paresthesias, hallucinations, dream abnormalities

Aseptic meningitis and meningoencephalitis, in one case accompanied by eosinophilia in the cerebrospinal fluid, have been reported in patients who took ibuprofen intermittently and did not have any connective tissue disease, psychomotor hyperactivity.

## **Dermatologic**

Incidence 3 to 9%: rash (including maculopapular type).

Incidence 1 to 3%: pruritus

Incidence less than 1%: vesiculobullous eruptions, urticaria, erythema multiforme, fixed eruption

Causal relationship unknown: alopecia, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalised exanthematous pustulosis (AGEP).

## **Cardiovascular**

Incidence less than 1%: congestive heart failure in patients with marginal cardiac function, elevated blood pressure (hypertension), angioedema, myocardial infarction, stroke (cerebrovascular accident).

Causal relationship unknown: arrhythmias (sinus tachycardia, sinus bradycardia, palpitations), hemorrhage (non-GI), Kounis syndrome.

## **Special Senses**

Incidence 1 to 3%: tinnitus

Incidence less than 1%: amblyopia (blurred and/or diminished vision, scotomata and/or changes in colour vision). Any patient with eye complaints during ibuprofen therapy should have an ophthalmological examination.

Causal relationship unknown: conjunctivitis, diplopia, optic neuritis.

### **Hematologic**

Incidence less than 1%: leukopenia, and decreases in haemoglobin and hematocrit.

Causal relationship unknown: haemolytic anaemia, thrombocytopenia, granulocytopenia, bleeding episodes (e.g., purpura, epistaxis, hematuria, menorrhagia).

### **Renal**

Causal relationship unknown: decreased creatinine clearance, polyuria, azotemia, nephritis, nephrotic syndrome, renal failure.

Like other non-steroidal anti-inflammatory drugs, ibuprofen inhibits renal prostaglandin synthesis, which may decrease renal function and cause sodium retention. Renal blood flow and glomerular filtration rate decreased in patients with mild impairment of renal function who took 1200 mg/day of ibuprofen for one week. Renal papillary necrosis has been reported. A number of factors appear to increase the risk of renal toxicity (*See 7 WARNINGS AND PRECAUTIONS*).

### **Hepatic**

Incidence less than 1%: hepatitis, jaundice, abnormal liver function (SGOT, serum bilirubin, and alkaline phosphatase), vanishing bile duct syndrome.

### **Endocrine**

Causal relationship unknown: gynecomastia, hypoglycaemic reaction.

Menstrual delays of up to two weeks and dysfunctional uterine bleeding occurred in nine patients taking ibuprofen, 400 mg t.i.d., for three days before menses.

### **Metabolic**

Incidence 1 to 3%: decreased appetite, oedema, fluid retention.

Fluid retention generally responds promptly to drug discontinuation (*See 7 WARNINGS AND PRECAUTIONS*).

### **General**

Incidence less than 1%: hypothermia

### **Respiratory**

Incidence less than 1%: asthma, bronchospasms

**Non-Prescription Experience: Literature (1992-1999) (at dosages ≤ 1200 mg/day)**

One researcher conducted an extensive analysis of published data concerning the relative safety of non-prescription doses of ibuprofen and acetaminophen. Of a total of 96 randomized and blinded trials, there were 10 trials of seven days' duration or less where the safety of both drugs was directly compared. In three of these trials, the incidence of adverse events was higher with acetaminophen; there were no reported adverse events in six trials; and one trial reported a higher incidence with ibuprofen. In this subset of 10 studies, it was reported that gastrointestinal adverse events were found to be the most common type of event reported and were predominantly dyspepsia, nausea, or vomiting. None of the GI events appeared to warrant follow-up from which the author inferred there were no serious gastrointestinal events.

It was concluded: "Although we recognize that the above mentioned data are very selective and are based on information derived from a variety of trial designs and populations, it is nonetheless instructive for indicating a relatively low incidence of severe adverse reactions with both drugs when taken at their respective non-prescription dosages."

A double-blind, placebo-controlled study (N=1246) was conducted to prospectively evaluate the gastrointestinal tolerability, as compared to placebo, of the maximum non-prescription dose and duration (1200 mg/day for 10 consecutive days) of ibuprofen use in healthy subjects representative of a non-prescription analgesic user population. Gastrointestinal adverse experiences were similar in the placebo and ibuprofen groups (67 out of 413, 16% with placebo vs. 161 out of 833, 19% with ibuprofen). There was no difference between the two groups in the proportion of discontinuing due to a gastrointestinal event. Gastrointestinal adverse experiences reported by ≥1% of subjects were: dyspepsia, abdominal pain, nausea, diarrhea, flatulence, and constipation. Seventeen (1.4%) subjects had positive occult blood tests: their frequency was comparable between treatments. When used as directed to treat episodic pain, non-prescription ibuprofen at the maximum dose of 1200 mg/day for 10 days, is well-tolerated.

In two multi-trial analyses a meta analysis, and a literature review, single doses of ibuprofen had a low incidence of gastrointestinal drug reactions, comparable to that of acetaminophen and placebo. Reports from spontaneous reporting systems in the United Kingdom, France and the United States, where a prescription is not needed for ibuprofen at a daily dose up to 1200 mg, confirm the medication's gastrointestinal safety and acceptability. A recently-completed large-scale randomized trial comparing non--prescription doses of acetylsalicylic acid, acetaminophen, and ibuprofen in 8677 adults found that the rates of significant adverse reactions were: aspirin 18.7%, ibuprofen 13.7%, and acetaminophen 14.5%.

Ibuprofen was not statistically different from acetaminophen. Total gastrointestinal events (including dyspepsia) and abdominal pain were less frequent with ibuprofen (4% and 2.8%, respectively) than with acetaminophen (5.3% and 3.9%) or aspirin (7.1% and 6.8%) [all p<

0.035]. It was concluded that “The overall tolerability of ibuprofen in this large-scale study was equivalent to that of paracetamol and better than that of [ASA].”

## 9 DRUG INTERACTIONS

### 9.1 Serious Drug Interactions

#### Serious Drug Interactions

- With acetaminophen may increase the risk of adverse renal effect.
- With acetylsalicylic acid (ASA) or other NSAIDs, may result in possible additive side effects (*See 2 CONTRAINDICATIONS*).
- With anticoagulants may increase the risk of GI adverse events (e.g., ulceration and bleeding).
- With antihypertensives the benefit and risk must be weighed individually.
- With digoxin may increase serum digoxin concentration and the risk of digoxin toxicity.
- With diuretics may reduce the diuretic effect.
- With hypoglycaemic agents (oral agents and insulin) may increase the risk of hypoglycaemia.
- With lithium may elevate plasma lithium levels, reduce renal lithium clearance and increase the risk of lithium toxicity.
- With methotrexate may increase the risk of methotrexate toxicity.

*See detailed information in 9.4 Drug-Drug Interactions.*

### 9.2 Drug Interactions Overview

MOTRIN® Liquid Gels 200 mg/ MOTRIN® Liquid Gels 400 mg is not recommended for concomitant use with any other NSAIDs, including ASA.

Documented or possible drug interactions with MOTRIN® Liquid Gels 200 mg/ MOTRIN® Liquid Gels 400 mg include acetaminophen, digoxin, anticoagulants, oral antidiabetic agents and insulin, antihypertensives, diuretics, methotrexate, lithium and other protein-bound drugs.

## 9.4 Drug-Drug Interactions

### Acetaminophen

Although interactions have not been reported, concurrent use with MOTRIN® Liquid Gels 200 mg/ MOTRIN® Liquid Gels 400 mg is not advisable: it may increase the risk of adverse renal effect.

### Acetylsalicylic acid (ASA) or other NSAIDs

The use of MOTRIN® Liquid Gels 200 mg/ MOTRIN® Liquid Gels 400 mg (Ibuprofen) in addition to any other NSAID, including ASA, is not recommended due to the absence of any evidence demonstrating synergistic benefits and the possibility of additive side effects. Animal studies show that aspirin given with NSAIDs, including ibuprofen, yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug. Single-dose bioavailability studies in normal volunteers have failed to show an effect of aspirin on ibuprofen blood levels. Correlative clinical studies have not been conducted.

No clinically meaningful loss of cardioprotection was observed, when patients on low dose ASA (81 mg) were administered 400 mg ibuprofen T.I.D., keeping in mind that combination NSAID therapy is associated with additive adverse reactions.

### Acetylsalicylic acid (ASA) Low Dose

Ibuprofen can interfere with the anti-platelet effect of low-dose ASA (81 – 325 mg per day). Long-term daily use of ibuprofen may render ASA less effective when used for cardioprotection and stroke prevention. To minimize this interaction, regular users of ibuprofen and low-dose, immediate-release ASA should take the ibuprofen at least one hour after or 11 hours before the daily low-dose ASA. The use of delayed-release (e.g. enteric coated) ASA is not recommended when using ibuprofen regularly. Healthcare professionals should advise consumers and patients regarding the appropriate concomitant use of ibuprofen and ASA.

### Antacids

A bioavailability study has shown that there was no interference with the absorption of ibuprofen when given in conjunction with an antacid containing aluminium hydroxide and magnesium hydroxide.

### Antihypertensives

Combinations of ACE inhibitors, angiotensin-II antagonists, or diuretics with NSAIDs might have an increased risk for acute renal failure and hyperkalemia. Blood pressure and renal function (including electrolytes) should be monitored more closely in this situation, as occasionally there can be a substantial increase in blood pressure.

Prostaglandins are an important factor in cardiovascular homeostasis and inhibition of their synthesis by NSAIDs may interfere with circulatory control. NSAIDs may elevate blood pressure

in patients receiving antihypertensive medication. Two meta analyses have observed this relationship for NSAIDs as a class and for certain NSAIDs in particular, but ibuprofen did not significantly affect blood pressure in either meta analysis. Consistent with this lack of effect, a study by Davies et al showed that ibuprofen 1600 mg/day for 14 days did not attenuate the antihypertensive effect of two  $\beta$ -adrenergic blockers. Houston et al. showed no effect of three weeks' therapy with ibuprofen on the antihypertensive efficacy of verapamil, but it is not known whether this lack of interaction extends to other classes of calcium channel blockers.

When renal perfusion pressure is reduced both prostaglandins and angiotensin II are important mediators of renal autoregulation. As a class, the combination of an NSAID and angiotensin converting enzyme inhibitor theoretically may have the potential to decrease renal function. One study found a clinically significant decrease in renal function in 4 of 17 patients treated with hydrochlorothiazide and fosinopril who received ibuprofen 2400 mg/day for one month. In contrast, Minuz found no effect on the antihypertensive effect of enalapril or on plasma renin or aldosterone following two days' treatment with ibuprofen 1200 mg/day.

The relationship of ibuprofen and antihypertensives is clearly not well defined. The benefits of concomitant medication should be analysed and compared to the potential risks before being prescribed. If ibuprofen is being recommended for long-term use, then periodic monitoring of blood pressure may be useful. Blood pressure monitoring is not necessary if ibuprofen is being recommended for short-term use as an analgesic.

### **Coumarin-type**

Numerous studies have shown that the concomitant use of NSAIDs and anticoagulants increases the risk of GI adverse events such as ulceration and bleeding. Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function, concurrent therapy of ibuprofen with warfarin requires close monitoring to be certain that no change in anticoagulant dosage is necessary. Several short-term controlled studies failed to show that ibuprofen significantly affected prothrombin time or a variety of other clotting factors when administered to individuals on coumarin-type anticoagulants. Nevertheless, the physician should be cautious when administering MOTRIN<sup>®</sup> Liquid Gels 200 mg/ MOTRIN<sup>®</sup> Liquid Gels 400 mg to patients on anticoagulants

### **Digoxin**

Ibuprofen has been shown to increase serum digoxin concentration. Increased monitoring and dosage adjustments of digitalis glycoside may be necessary during and following concurrent ibuprofen therapy.

### **Diuretics**

Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with ibuprofen, the patient should be observed closely for signs of renal failure as well as to assure diuretic efficacy.



**Glucocorticoids:**

Some studies have shown that the concomitant use of NSAIDs and oral glucocorticoids increases the risk of GI adverse events such as ulceration and bleeding. This is especially the case in older (> 65 years of age) individuals.

**H-2 antagonists**

In studies with human volunteers, coadministration of cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen serum concentrations.

**Hypoglycaemic Agents**

Ibuprofen may increase hypoglycaemic effects of oral antidiabetic agents and insulin.

**Lithium**

Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers. The mean minimum lithium concentration increased 15% and the renal clearance of lithium was decreased by 19% during this period of concomitant drug administration. This effect has been attributed to inhibition of renal prostaglandin synthesis by ibuprofen. Thus, when ibuprofen and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.

**Methotrexate**

Ibuprofen as well as other NSAIDs has been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This may indicate that ibuprofen could enhance the toxicity of methotrexate. Caution should be used when ibuprofen is administered concomitantly with methotrexate.

**Selective Serotonin Reuptake Inhibitors (SSRIs)**

Studies report an increased risk of gastrointestinal (GI) ulceration and bleeding when ibuprofen as well as other NSAIDs are taken concomitantly with selective serotonin reuptake inhibitors (SSRIs) than when either class of drugs is taken alone (See Warnings and Precautions – Gastrointestinal).

**Other Drugs**

Although ibuprofen binds extensively to plasma proteins, interactions with other protein-bound drugs occur rarely. Nevertheless, caution should be observed when other drugs, also having a high affinity for protein binding sites, are used concurrently. No interactions have been reported when ibuprofen has been used in conjunction with probenecid, thyroxine, antibiotics, cyclosporine, phenytoin, corticosteroids or benzodiazepines.

**9.5 Drug-Food Interactions**

Interactions with food have not been established.

## 9.6 Drug-Herb Interactions

Interactions with herbal products have not been established.

## 9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

# 10 CLINICAL PHARMACOLOGY

## 10.1 Mechanism of Action

Ibuprofen, like all nonsteroidal anti-inflammatory drugs (NSAIDs), is an analgesic, antipyretic, and anti-inflammatory medication. There is strong evidence to support the view that the main mechanism of action of ibuprofen (like other NSAIDs) is related to decreasing prostaglandin biosynthesis.

Prostaglandins are naturally-occurring fatty acid derivatives that are widely distributed in the tissues. They are believed to be a common factor in the production of pain, fever, and inflammation. Prostaglandins are believed to sensitise tissues to pain- and inflammation-producing mediators such as histamine, 5-hydroxytryptamine, and kinins. The enzyme catalysing the committed step in prostaglandin biosynthesis is prostaglandin endoperoxide synthase, also known as cyclooxygenase. There is significant evidence that the main mechanism of analgesic/antipyretic action of NSAIDs is prostaglandin biosynthesis inhibition. Other pharmacologic effects such as lysosome and plasma membrane 26etabolizing26 have been observed, but the potential relevance of these effects to ibuprofen-induced analgesia and antipyresis is unclear.

A recent study confirmed that ibuprofen 400 mg provided a significantly faster onset of relief as measured by first perceptible relief, meaningful relief, per cent attaining complete relief, and superior overall analgesic efficacy compared to acetaminophen 1000 mg for relief of episodic tension-type headache.

## 10.2 Pharmacodynamics

After single oral doses of 20 to 150 mg/kg of C<sup>14</sup> labelled ibuprofen rats, the peak plasma level occurred at or before the earliest time examined (20 minutes in the 20 mg/kg group and 45 minutes in the 150 mg/kg group) and peak levels occurred with 45 minutes of dosing in nearly all tissues examined. The concentration in plasma and tissue decreased to very low levels by six hours after the 20 mg/kg dose and by 17 hours after the 150 mg/kg dose. Sixteen to 38% of the daily dose of ibuprofen was excreted in the urine.

A similar dose was given to dogs for periods of up to six months with no evidence of accumulation of the drug or its metabolites.

### Inhibition of Platelet Aggregation in Animals

Like many other NSAIDs, ibuprofen inhibits platelet aggregation, as demonstrated by preventing platelet disposition in aortopulmonary arterial bypass grafts in the dog. The drug's protective action against fatal pulmonary embolism in rabbits injected intravenously with arachidonic acid may also relate to platelet inhibition. Various prostaglandins and thromboxane A<sub>2</sub> (TXA<sub>2</sub>), are important factors in normal platelet aggregation. Cyclooxygenase inhibition reduces TXA<sub>2</sub> production and release, thereby reducing platelet aggregation. Ibuprofen may also reduce platelet membrane fluidity, which reduces aggregation, but it is not known to what extent TXA<sub>2</sub> synthesis inhibition is involved in this effect.

Two metabolites of ibuprofen were isolated from the urine of patients who had been treated for one month with the drug. The metabolites were identified as 2-4', (2-hydroxy-2-methylpropyl) phenylpropionic acid (metabolite A) and 2-4' (2-carboxpropyl) phenylpropionic acid (metabolite B). About 1/3 of the dose was excreted in the urine of patients as metabolite B, 1/10 as unchanged ibuprofen and 1/10 as metabolite A. The remainder of the dose could not be identified in the urine.

Effect of Ibuprofen on Platelet Aggregation, Bleeding and Clotting Times in Normal Volunteers  
Platelet aggregation studies using the method of Sekhar were performed. Platelet aggregation fell significantly at a dosage of 1800 mg per day of ibuprofen when given over a period of 28 days.

Ibuprofen was also found to influence ADP induced aggregation to a lesser extent than that influenced by collagen. Platelet aggregation induced by recalcification of citrated platelet-rich plasma (a thrombin induced reaction) was not influenced by ibuprofen treatment. Likewise, ibuprofen did not affect whole blood clotting time on recalcification or prothrombin time. Bleeding time performed two hours after the administration of ibuprofen showed a significant dose related increase.

Experimental data suggest that ibuprofen may inhibit the effect of low dose ASA (81 – 325 mg per day) on platelet aggregation when they are dosed concomitantly. In one study, when a single dose of ibuprofen 400 mg was taken within 8 hours before or within 30 minutes after immediate release ASA dosing, a decreased effect of ASA on the formation of thromboxane or platelet aggregation occurred. However, the limitations of these data and the uncertainties regarding extrapolation of *ex vivo* data to the clinical situation imply that no firm conclusions can be made for regular ibuprofen use, and no clinically relevant effect is considered to be likely for occasional ibuprofen use.

### **10.3 Pharmacokinetics**

#### **Absorption**

Ibuprofen is rapidly and almost completely absorbed. Peak serum concentration occurs within 1-2 hours in adults. Ibuprofen capsules contain solubilized ibuprofen which has peak serum

concentrations within 36 to 42 minutes. In febrile children ages 3 months to < 12 years, the time of peak serum concentration was 1.60 and 1.54 hours for ibuprofen 5 mg/kg and 10 mg/kg, respectively. Nahata found a time to peak concentration of 1.1 and 1.2 hours for these respective doses. A similar study in febrile children by Walson which used an ibuprofen suspension showed a time of peak serum concentration of 1.3 and 1.7 hours for ibuprofen 5 mg/kg and 10 mg/kg, respectively. Walson also found that mean ibuprofen plasma concentration at one hour was  $21.7 \pm 6.7$  and  $28.4 \pm 15.2$  mcg/mL for 5 mg/kg and 10 mg/kg, respectively. Food decreases the rate but not the extent of absorption.

### **Distribution:**

The volume of distribution in adults after oral administration is 0.1-0.2 L/kg. In febrile children the volume of distribution is 0.18 and 0.22 L/kg for ibuprofen 5 mg/kg and 10 mg/kg, respectively.

At therapeutic concentrations ibuprofen is highly bound to whole human plasma and to site II of purified albumin. There is no appreciable plasma accumulation of ibuprofen or its metabolites with repeated doses.

### **Metabolism:**

Ibuprofen is a racemic mixture of R-(-) ibuprofen and S-(+) ibuprofen. R-(-) ibuprofen undergoes extensive enantiomeric conversion to S-(+) ibuprofen in humans, averaging between 53% and 65%. S-(+) ibuprofen is believed to be the pharmacologically more active enantiomer. Two major metabolites, 2-[4-(2-carboxypropyl)phenyl] propionic acid and 2-[4-(2-hydroxy-2-methylpropyl)propionic acid, have been identified in plasma and urine. The metabolites 1-hydroxyibuprofen and 3-hydroxyibuprofen have also been found in urine in very small concentrations. Cytochrome P450 (CYP) 2C9 has been identified as the most important catalyst for formation of all oxidative metabolites of R-(-) and S-(+) ibuprofen. Approximately 80% of a dose is recovered in urine, primarily as carboxymetabolites and conjugated hydroxymetabolites. Ibuprofen does not appear to induce the formation of drug metabolizing enzymes in the rat.

### **Elimination**

Ibuprofen's plasma half-life in adults is 1.5-2.0 hours. In febrile children the plasma half-life is 1.65 and 1.48 hours for ibuprofen 5 mg/kg and 10 mg/kg, respectively. Parent drug and metabolites are primarily excreted in the urine; bile and faeces are relatively minor elimination routes. Total recovery in urine is between 70% and 90% of the administered dose within 24 hours.

There is no evidence of a differential metabolism or elimination of ibuprofen in the elderly. A pharmacokinetic evaluation of ibuprofen in geriatric subjects (65 to 78 years) compared with young adult subjects (22 to 35 years) found that there was no clinically significant difference in

the kinetic profiles of ibuprofen for these age groups. Furthermore, there was no statistically significant difference between the two populations in the urinary excretion pattern of the drug and its major metabolites.

The pharmacokinetics of ibuprofen have also been evaluated in children, in whom the metabolism has been shown to be similar to that reported for adults. Walson reported that for ibuprofen 10 mg/kg given to children under 12 years of age, peak plasma concentration occurred at 1.5 hours and then declined with a plasma half-life of 1.8 hours. Thus, ibuprofen appears to exhibit a similar pharmacokinetic profile in all age groups examined.

### **Special Populations and Conditions**

- **Pregnancy and Breast-feeding**

- Breast Milk and Placental Transport

- Ibuprofen excretion in breast milk following ingestion of one 400 mg ibuprofen tablet every 6 hours for five doses was below the level (i.e., 1 g/mL) of detection.<sup>17</sup> However, a later study using a more sensitive assay showed ibuprofen to be rapidly excreted in breast milk 30 minutes following oral ingestion of 400 mg of ibuprofen at a concentration of 13 ng/mL. A milk: plasma ratio of 1:126 was determined and the exposure of a suckling infant was calculated to be approximately 0.0008% of the maternal dose. It is not known whether ibuprofen crosses the placenta.

### **11 STORAGE, STABILITY AND DISPOSAL**

MOTRIN<sup>®</sup> Liquid Gels 200 mg/ MOTRIN<sup>®</sup> Liquid Gels 400 mg should be stored at room temperature between 15°C to 30°C. Protect from heat and humidity.

### **12 SPECIAL HANDLING INSTRUCTIONS**

Not applicable.

## PART II: SCIENTIFIC INFORMATION

### 13 PHARMACEUTICAL INFORMATION

#### Drug Substance

Proper name: Ibuprofen

Chemical name: (±) α-methyl-4- (2-methylpropyl) benzeneacetic acid


Other Names: (±)- p-isobutylhydratropic acid

(±) -2-(p-isobutylphenyl) propionic acid

Molecular formula and molecular mass: C<sub>13</sub>H<sub>18</sub>O<sub>2</sub>

206.28 g/mol

Structural formula:



Physicochemical properties:

Physical characteristics:	White or almost white powder or crystals with a characteristic odour.
Solubilities:	Low solubility in water: soluble 1 in 1.5 of alcohol, 1 in 1 of chloroform, 1 in 2 of ether, and 1 in 1.5 of acetone. Ibuprofen is also soluble in an aqueous solution of alkali hydroxides and carbonates.
pKa and pH values:	pH: 4.6 to 6.0, in a solution of 1 in 20
Melting Point:	75°C to 77°C

### 14 CLINICAL TRIALS

#### 14.1 Trial Design and Study Demographics

There is considerable evidence in the world literature documenting the efficacy of 200 to 400 mg doses of ibuprofen in the treatment of mild to moderate pain in a broad range of pain models. In studies using ibuprofen 400 mg tablets in the dental impaction pain model, the median time to confirmed perceptible pain relief ranged from 24 to 48 minutes after dosing, and the median time to use of rescue medication, ranged from 5.7 to 10.1 hours (*See 14.2 Study Results*).

## 14.2 Study Results

Published studies have documented the efficacy of 200-mg and 400-mg doses of ibuprofen in treating mild to moderate pain, including sore throat pain, headache and muscle aches in adults. The antipyretic efficacy of ibuprofen has been demonstrated in adults at doses of 200 and 400 mg.

### ***Dental Pain***

A double-blind, randomized study showed that ibuprofen 400 mg relieved dental pain following removal of impacted third molars significantly better than acetaminophen and placebo. Several other comparative dental studies have described similar results.

Multiple published studies have demonstrated the efficacy of ibuprofen 400 mg compared to placebo, several different Cyclooxygenase 2 (COX-2) inhibitors, and other NSAIDs in the treatment of patients with moderate or severe pain following the extraction of two or more third molar teeth.

The results of the trials utilized the primary end points of total pain relief at 8 hours (TOTPAR8) Pain Intensity Difference (PID) and Sum of Pain Intensity Differences (SPID) as pain relief measures. Duration of effect was assessed using the median or mean time (hours) to use rescue medication. Global evaluation of pain relief at 8 hours was also used with subjects asked to report their level of pain relief after 8 hours.

The duration of effect was 8 hours (range from 6 to 10 hours).

In four similar randomized, single dose, placebo and active comparator controlled, parallel group studies, the analgesic efficacy of ibuprofen 400 mg was compared to placebo and various COX-2 inhibitors at different doses when treating postoperative dental pain. The studies established that ibuprofen 400 mg had median duration of effect (in hours) of 8.9, 10.0, 10.1, and 6.1, respectively, while placebo's median duration of effect was 1.5, 1.6, 2.1 and 2.4, respectively. In all 4 studies, the pain relief measure of TOTPAR8 revealed ibuprofen 400 mg to be statistically significantly superior to placebo with  $p < 0.001$ . In three of the studies, the global evaluation of pain relief at 8 hours was reported and 73%, 74%, and 78% of the ibuprofen 400 mg patients reported good, very good or excellent pain relief after 8 hours compared to 19%, 7%, and 19% of placebo patients. Median time to onset of pain relief (minutes) was also proven to be statistically significantly different to placebo (>240 minutes) compared to the Ibuprofen 400 mg patients (24, 30, 30 minutes, respectively).

In another randomized, single dose, double blind placebo and active comparator controlled, parallel group study, the analgesic efficacy of lumiracoxib 100 (n=51) and 400 mg (n=50) was compared with ibuprofen 400 mg (n=51) and placebo (n=50). The primary endpoint was PID and the secondary measures included time to onset of analgesia and duration of effect. The results showed the PID scores for ibuprofen 400 mg were statistically superior to placebo across all time points from 1 to 12 hours. Median time to onset of pain relief was 12 hours or

more for placebo, 41.5 minutes for ibuprofen, which was statistically significantly different versus placebo. The duration of effect were ~2 hours placebo and ibuprofen ~8 hours ( $p < 0.001$  vs. placebo).

Several other randomized, single dose, double blind placebo and active comparator controlled, parallel group studies, the analgesic efficacy of ibuprofen 400mg was compared to placebo and various NSAIDs. The studies reported that the duration of analgesic effect, as measured by the median time to use of rescue medication, was 8.5, 5.7, 6.3, 6 and 5.8 hours in patients taking 400mg ibuprofen while placebo duration of analgesic effect was 4.5, 2.8, 2.7, 1.1, 1.4 hours, respectively. The studies utilized either PID, SPID or pain relief combined with pain intensity difference (PRID) pain relief measures. The results all showed that Ibuprofen 400mg groups were statistically significantly different at 8 hours versus placebo ( $p < 0.05$ ).

### ***Muscle Aches***

A double-blind, randomized study showed that ibuprofen 400 mg every four hours for a total of three doses relieved muscle soreness following exercise significantly better than acetaminophen 1000 mg and placebo every four hours.

### ***Headache***

A double-blind, randomized study showed that ibuprofen 400 mg relieved headache pain significantly better than acetaminophen 1000 mg and placebo. Another double-blind, placebo controlled, randomized study showed that ibuprofen 400 mg began to exert a significant analgesic effect on headache within 30 minutes after dosing. A third double-blind, randomized study confirmed that ibuprofen 400 mg provided significantly faster onset of relief as measured by first perceptible relief, percent attaining complete relief, and superior overall analgesic efficacy compared to acetaminophen 1000 mg for relief of episodic tension-type headache.

### ***Dysmenorrhea***

Several studies demonstrate the significant effect of ibuprofen compared to placebo or other active analgesics on uterine pain and cramping.

### ***Fever***

The antipyretic efficacy of ibuprofen has been demonstrated in adult fever.

### ***Pain of Osteoarthritis***

Controlled clinical studies in adults provide substantial evidence of the safety and efficacy of ibuprofen at doses of 1200 mg or less per day in relieving the pain of osteoarthritis. These studies support an indication for the relief of pain from inflammation associated with conditions including:

- arthritis
- physical or athletic overexertion (e.g. sprains or strains).



### **Sore Throat Pain**

A double-blind, randomized study showed that ibuprofen 400 mg relieved sore throat pain significantly better than placebo and acetaminophen.

Ibuprofen has also been studied in other pain models including migraine with equally effective pain relief results.

### **14.3 Comparative Bioavailability Studies**

A randomized, single dose, double blinded, standard randomized 2-way crossover comparative bioavailability study, conducted under fasting conditions was performed on healthy adult volunteers. The results obtained from 16 volunteers who completed the study are summarized in the following table. The rate and extent of absorption of ibuprofen were measured and compared following a single oral dose (1 x 400 mg) of IBUPROFEN CAPSULES, 400 mg (Catalent Ontario Ltd.) and Advil Extra Strength Liqui-Gels® 400 mg (distributed by Wyeth Consumer Health Inc, Canada).

Summary Table of the Comparative Bioavailability Data Ibuprofen (A single 400 mg dose: 1 x 400 mg) From Measured Data/Fasting Conditions Geometric Mean Arithmetic Mean (CV %)				
Parameter	Test*	Reference <sup>†</sup>	Ratio of Geometric Means (%)	90% Confidence Interval (%)
AUC <sub>T</sub> (mcg.h / mL)	121.828	119.184	102.2%	98.51 – 106.07 %
	123.910 (20.2)	121.602 (21.2)		
AUC <sub>RefTmax</sub> (mcg.h / mL)	12.955	11.003	117.7 %	102.64 – 135.06%
	14.124 (34.2)	11.886 (36.6)		
AUC <sub>I</sub> (mcg.h / mL)	124.178	122.215	101.6%	97.89 – 105.47%
	126.438 (20.9)	124.971 (22.5)		
C <sub>max</sub> (mcg / mL)	44.551	40.667	109.6%	102.67 – 116.90%
	44.972 (13.9)	41.269 (16.8)		

Summary Table of the Comparative Bioavailability Data Ibuprofen (A single 400 mg dose: 1 x 400 mg) From Measured Data/Fasting Conditions Geometric Mean Arithmetic Mean (CV %)				
Parameter	Test*	Reference <sup>†</sup>	Ratio of Geometric Means (%)	90% Confidence Interval (%)
T <sub>MAX</sub> <sup>§</sup> (h)	0.625 (0.417 – 1.000)	0.667 (0.333 – 1.000)		
T <sub>½</sub> <sup>€</sup> (h)	2.044 (13.0)	2.155 (16.8)		

\* IBUPROFEN CAPSULES, 400 mg (Catalent Ontario Ltd.)

<sup>†</sup> Advil Extra Strength Liqui-Gels 400 mg (distributed by Wyeth Consumer Health Inc, Canada) were purchased in Canada.

<sup>§</sup> Expressed as the median (range).

<sup>€</sup> Expressed as arithmetic mean (CV%) only.

## 15 MICROBIOLOGY

Not applicable. No microbiological information is required for this drug product.

## 16 NON-CLINICAL TOXICOLOGY

### General Toxicology:

#### Single Dose Toxicity Studies

Single dose toxicity studies have been conducted using mice, rats, and dogs.

The LD<sub>50</sub> values for ibuprofen, expressed as mg/kg of body weight are as follows:

Mouse:	Oral	800 mg/kg
	Intraperitoneal	320 mg/kg

Rat:	Oral	1600 mg/kg
	Subcutaneous	1300 mg/kg

Acute signs of poisoning were prostration in mice, and sedation, prostration, loss of righting reflex and laboured respiration in rats. Death occurred within 3 days from perforated gastric ulcers in mice and intestinal ulceration in rats, irrespective of the route of administration.

Following single ibuprofen doses of 125 mg/kg and above to dogs effects were observed including emesis, transient albuminuria, faecal blood loss and erosions in the gastric antrum and pylorus; no ill effects were seen with 20 or 50 mg/kg doses.

### Multiple Dose Studies

The no-effect level was determined using groups of 10 male and 10 female rats which were dosed orally for 26 weeks with 180, 60, 20 or 7.5 mg/kg ibuprofen in 0.4% hydroxyethyl cellulose. The control group consisted of 20 males and 20 females which received 0.4% hydroxyethyl cellulose. Rats were weighed three times daily and blood samples were obtained in the final week of dosing. The rats were sacrificed the day after the last dose and the internal organs examined.

Rats receiving ibuprofen for 26 weeks grew normally except for males on 180 mg/kg/day, which gained significantly less weight than the controls. One male rat receiving 180 mg/kg/day died due to intestinal lesions and the death was thought to be treatment-related. Both males and females receiving 180 mg/kg/day were anaemic; leukocyte count and plasma glutamic pyruvic transaminase activities were not significantly altered. The organ to body weight ratio of males given 180 mg/kg/day was typically greater than normal. For some organs, this was because the males weighed less than the controls. Organs that were enlarged were the liver, kidney, and spleen. The same organs were also enlarged in females receiving 180 mg/kg/day, although these females were similar in body weight to the controls. In addition, the combined seminal vesicle and prostate weight was subnormal and uterine weight was increased. The thyroid gland of males receiving 180, 60, 20 mg/kg/day exhibited a slight increase in weight, which was the same for the three doses, however no such increase was observed in the females. There were no significant histological changes observed in rat tissues except for the presence of intestinal ulcers in 1 male and 3 females receiving 180 mg/kg/day.

The above experiment was adapted to establish whether the effects of ibuprofen treatment on rats were reversible when dosing ended. In this instance, rats were administered 180, 60, or 20 mg/kg/day ibuprofen for 13 weeks instead of 26 weeks, whereupon half the animals in each group were sacrificed and the remaining rats were maintained, undosed, for three weeks and then sacrificed. Haematological examinations were performed after 4, 8, and 12 weeks of treatment.

Results obtained from the dosing phase of this 13-week experiment reflected the results obtained previously, where rats were dosed for 26 weeks. Males receiving 180 mg/kg/day had enlarged kidneys, spleen, and testes; while those on lower doses had normal organ weights. Females on all three doses had enlarged kidneys, the extent of which was dose-dependent. Enlargement of the liver and ovaries was observed in females receiving 180 mg/kg/day, and of the spleen and ovaries on those on 60 mg/kg/day. None of the enlarged organs were histologically abnormal. Three weeks following withdrawal of treatment, the organ to body weight ratios had completely or almost completely returned to normal. Rats receiving 180 mg/kg/day were anaemic from week 4 of dosing and when examined after the final dose, were found to have intestinal lesions. These effects were not seen at the lower doses, thereby confirming the results of the first experiment. Since the highest dose of 180 mg/kg/day was only moderately toxic, an additional group of rats were dosed with 540 mg/kg/day. All these rats died or were killed *in extremis* after 4 days' dosing. All had intestinal ulceration with

peritonitis, and some also had slight renal tubular dilation.

The primary toxic effect of ibuprofen in rats is intestinal damage. Ibuprofen alters the organ to body weight ratio of certain organs, such as the liver, kidneys, gonads, and the secondary sex organs, although no histological abnormalities have occurred and the effect is reversible. The liver and kidney enlargement may be a reflection of work hypertrophy associated with the metabolism and excretion of the compound, whereas the significance of the effect on other organs is unknown. When administered in lethal doses, ibuprofen produces mild kidney lesions in addition to the intestinal damage.

#### **Carcinogenicity:**

Thirty male and thirty female rats were given 180 mg/kg/day of ibuprofen orally for 55 weeks and 60 mg/kg/day for the next 60 weeks. The only specific pathological effect observed was intestinal ulceration. There was no evidence of tumour induction and it is concluded that ibuprofen is not carcinogenic in the rat.

#### **Reproductive and Developmental Toxicology:**

##### **Teratology Study in Rabbits**

New Zealand white rabbits were given 0, 7.5, 20 and 60 mg/kg daily of ibuprofen from day 1 to day 29 of pregnancy. The mean foetal weight was unaffected; litter size was unaffected at the lower doses. Congenital malformations did occur in both treated and untreated groups with no consistent pattern except for one litter of 4 young with cyclopia. The results of this experiment indicate that ibuprofen is not teratogenic when given in toxic doses to rabbits.

##### **Teratology Study in Rats**

Newly-mated female albino rats were given ibuprofen in doses of 0, 7.5, 20, 60 and 180 mg/kg/day from day 1 to day 20 of pregnancy; ibuprofen exhibited no embryotoxic or teratogenic effects even when administered at ulcerogenic doses.

##### **Penetration of Ibuprofen into the Rabbit and Rat Fetus**

Rabbits and rats in late pregnancy were given single oral doses of 60 and 20 mg/kg respectively of C<sup>14</sup> labelled ibuprofen. Rabbits were killed three hours after dosing and rats killed 1.5 hours after dosing when maternal and foetal blood was collected. Similar concentrations of radioactive ibuprofen were detected in both the mother and foetus indicating that the drug and its metabolites readily crossed the placental barrier into the foetal circulation.

## **17 SUPPORTING PRODUCT MONOGRAPHS**

1. Advil® Liqui-Gels,. Submission Control No: 238543. Product Monograph – Pfizer Consumer Healthcare. Date of Revision: May 7, 2020.

## **PATIENT MEDICATION INFORMATION**

### **READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE**

#### **MOTRIN® LIQUID GELS 200 mg**

#### **Ibuprofen Capsules (free acid and potassium salt)**

Read this carefully before you start taking **MOTRIN® LIQUID GELS 200 mg** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **MOTRIN® LIQUID GELS 200 mg**.

#### **Serious Warnings and Precautions**

- Caution in those with heart failure, high blood pressure or other conditions that may cause excess fluid collecting in tissues.
- Caution in patients prone to gastrointestinal tract irritation, including those with a history of peptic ulcer. The chance of stomach bleeding is higher if you are: age 60 or older, have had stomach ulcers or bleeding problems, take a blood thinner or steroid drug, take with other drugs containing an NSAID like acetylsalicylic acid (ASA), ibuprofen, naproxen, or prescription anti-inflammatory drugs, have 3 or more alcoholic drinks every day while using this product.
- Caution in patients at risk of kidney problems, including the elderly or those using diuretics.
- Stop use immediately if you have difficulty or pain when urinating.
- Talk to your doctor if you are trying to conceive, in your first or second trimester of pregnancy or if breastfeeding.

#### **What is MOTRIN® LIQUID GELS 200 mg used for?**

MOTRIN® Liquid Gels 200 mg provides fast and effective relief of pain from:

- muscle aches and pain, joint and body pain, backache, muscle sprains and strains,
- pain of inflammation associated with conditions including:
  - arthritis,
  - physical or athletic overexertion (e.g. sprains or strains),
- headache including tension headache,
- dental pain,
- menstrual pain,
- aches and pain due to the common cold and flu.

Temporary relief of mild to moderate migraine headaches including associated symptoms of nausea, and sensitivity to light and sound.

Reduction of fever.

### **How does MOTRIN® LIQUID GELS 200 mg work?**

MOTRIN® (ibuprofen) Liquid Gels 200 mg starts to work fast and treats pain where it starts. Ibuprofen is a member of a class of drugs called non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs work within the body by blocking the production of substances, called prostaglandins, which are involved in the development of pain and inflammation.

### **What are the ingredients in MOTRIN® LIQUID GELS 200 mg?**

Medicinal ingredients: Ibuprofen (free acid and potassium salt).

Non-medicinal ingredients: gelatin, pharmaceutical ink, polyethylene glycol, potassium hydroxide, propylene glycol, purified water and sorbitol.

### **MOTRIN® LIQUID GELS 200 mg comes in the following dosage forms:**

Capsules, 200 mg

### **Do not use MOTRIN® LIQUID GELS 200 mg if:**

- You are:
  - taking acetylsalicylic acid (ASA) or any other non-steroidal anti-inflammatory medication including any other ibuprofen product.
  - allergic or have had a reaction to ibuprofen, acetylsalicylic acid (ASA), other non-steroidal anti-inflammatory drugs (NSAIDs) or salicylates, or to any ingredient in the formulation (see Non-medicinal ingredients above). Allergic reactions may appear as hives, difficulty breathing, shock, skin reddening, rash or blisters, swelling of the face or throat, or sudden collapse.
  - dehydrated (significant fluid loss) due to vomiting, diarrhea or lack of fluid intake.
  - in your third trimester of pregnancy.
  
- You have:
  - nasal polyps (growth inside your nose), or allergic manifestations such as asthma, anaphylaxis (sudden severe life-threatening anaphylactic reactions), urticaria/hives, rhinitis (stuffed or runny nose that may be due to allergies), skin rash or other allergic symptoms.
  - active or recurrent stomach ulcer, gastrointestinal (GI) bleeding, or active inflammatory bowel disease (e.g. Crohn's, colitis).

- serious liver or kidney disease.
  - systemic lupus erythematosus.
  - high potassium in the blood.
- You recently had or are about to have heart surgery.

**To help avoid side effects and ensure proper use, talk to your healthcare professional before you take MOTRIN® LIQUID GELS 200 mg. Talk about any health conditions or problems you may have, including if you:**

- have previous or current stomach ulcers, high blood pressure, asthma, heart failure, heart disease or thyroid disease, kidney or liver disease, glaucoma, diabetes, alcoholism, a history of stomach bleeding, or any other serious disease or condition.
- are taking any drug including over the counter drugs.
- are pregnant or breastfeeding.
- have a blood-clotting disorder (e.g. hemophilia, sickle cell anemia, etc.).
- are on a special diet (e.g. low-sodium).

**Other warnings you should know about:**

- Use with caution in the elderly.
- Long-term continuous use may increase the risk of heart attack or stroke.
- The use of NSAIDs, like MOTRIN® LIQUID GELS 200 mg, in the second trimester of pregnancy should be restricted to the lowest dose necessary for shortest possible duration.
- At 20 weeks or later in pregnancy, your use of NSAIDs may need to be monitored by a doctor due to the rare risk of kidney problems in the unborn baby which may result in decreased amniotic fluid volume and other complications.

**Stop use and ask a doctor if**

- you show signs of stomach bleeding
- pain worsens or lasts more than 5 days
- fever worsens or lasts more than 3 days
- any new symptoms appear

**Driving and using machines:** If you become drowsy, dizzy or lightheaded, do not drive or operate machinery and contact your doctor or pharmacist.

**Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.**

**The following may interact with MOTRIN® LIQUID GELS 200 mg:**

- acetaminophen
- anticoagulants (blood thinners)
- ASA or other NSAIDs
- digoxin
- diuretics (water pills)
- lithium
- medications for high blood pressure
- methotrexate
- oral antidiabetic agents and insulin
- protein-bound drugs including probenecid, thyroxine, antibiotics, cyclosporine, phenytoin, corticosteroids or benzodiazepines
- selective serotonin reuptake inhibitors (medicine used to treat depression)

Do not use MOTRIN® Liquid Gels 200 mg if you are taking daily low dose ASA (81 – 325 mg), without talking to a doctor or pharmacist. Ibuprofen may interfere with the preventive benefits of ASA.

**How to take MOTRIN® LIQUID GELS 200 mg:**

Do not give to children under 12. Children's MOTRIN® formulations are available to treat children under 12 years of age.

Stomach upset is one of the common problems with NSAIDs. To lessen stomach upset, take this medicine immediately after a meal or with food or milk. If stomach upset (indigestion, nausea, vomiting, stomach pain or diarrhoea) occurs and continues, contact your doctor.

**Usual dose:**

For migraine headaches: Adults and children over 12:

Take 1 (every 4 hours) or 2 (every 6-8 hours) capsules at the first sign of symptoms as needed. Do not exceed six capsules in 24 hours, unless directed by a doctor.

For all other uses: Adults and children over 12:

Take 1 (every 4 hours) or 2 (every 6-8 hours) capsules as needed. Do not exceed 6 capsules in 24 hours, unless directed by a doctor.

Use the lowest effective dose for the shortest duration.

**Overdose:**

If you think you, or a person you are caring for, have taken too much MOTRIN® LIQUID GELS 200 mg, contact a healthcare professional, hospital emergency department, or regional poison



control centre immediately, even if there are no symptoms.

**Missed Dose:**

Take the missed dose as soon as you remember. If it is almost time for your next dose, wait until then to take your medicine and skip the missed dose. Do not take two doses at the same time.

**What are possible side effects from using MOTRIN® LIQUID GELS 200 mg?**

These are not all the possible side effects you may have when taking MOTRIN® LIQUID GELS 200 mg. If you experience any side effects not listed here, tell your healthcare professional.

The most common side effects with this medication are indigestion, nausea, vomiting, heartburn, dizziness, and skin rashes.

The other side effects, which might be seen, are sudden abdominal pain or long-term abdominal pain with the loss of appetite and/or jaundice and/or new onset of itching, diarrhoea, bloating, constipation, abdominal cramp, headache, nervousness, drowsiness, itching, decreased appetite, sleeplessness and fluid retention.

If unusual symptoms or any of the following reactions develop during treatment, stop use and see a doctor immediately.

<b>Serious side effects and what to do about them</b>			
<b>Symptom / effect</b>	<b>Talk to your healthcare professional</b>		<b>Stop taking drug and get immediate medical help</b>
	<b>Only if severe</b>	<b>In all cases</b>	
<b>UNCOMMON</b>			
Chills, fever, muscle aches or pains, or other flu-like symptoms shortly before or together with a skin rash		√	
Bloody or black tarry stools		√	
Hives or itching, skin reddening, blisters		√	
Blurred vision		√	
Swelling of feet or lower legs		√	
Hearing problems (ringing or buzzing in the ears)		√	
Mental confusion or depression		√	
Shortness of breath, chest pain, trouble breathing, asthma,		√	

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
sinusitis (nasal congestion), wheezing, or tightness in the chest			
Vomiting blood		√	
Yellow discoloration of the skin or eyes, with or without fatigue		√	
Any changes in the amount or colour of your urine (such as dark; red or brown), any pain or difficulty experienced in urination, loss of appetite, dizziness, or light headedness		√	
Stomach pain	√		
Heart Failure			√

In addition to checking with your doctor, if these serious side effects occur, stop taking this medication.

Side effects may be minimized by using the smallest dose for the shortest duration of time.

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

### Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

**Storage:**

Store at 15 – 30°C. Protect from heat and humidity.

Keep out of reach and sight of children. This package contains enough medicine to seriously harm a child.

**If you want more information about MOTRIN® LIQUID GELS 200 mg:**

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website [www.motrin.ca](http://www.motrin.ca), or by calling 1-800-6 MOTRIN / 1-888-666-8746.

This leaflet was prepared by McNeil Consumer Healthcare, division of Johnson & Johnson Inc.,

Last Revised: April 5, 2023

## **PATIENT MEDICATION INFORMATION**

### **READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE**

#### **MOTRIN® LIQUID GELS 400 mg**

#### **Ibuprofen Capsules (free acid and potassium salt)**

Read this carefully before you start taking **MOTRIN® LIQUID GELS 400 mg** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **MOTRIN® LIQUID GELS 400 mg**.

#### **Serious Warnings and Precautions**

- Caution in those with heart failure, high blood pressure or other conditions that may cause excess fluid collecting in tissues.
- Caution in patients prone to gastrointestinal tract irritation, including those with a history of peptic ulcer. The chance of stomach bleeding is higher if you are: age 60 or older, have had stomach ulcers or bleeding problems, take a blood thinner or steroid drug, take with other drugs containing an NSAID like acetylsalicylic acid (ASA), ibuprofen, naproxen, or prescription anti-inflammatory drugs, have 3 or more alcoholic drinks every day while using this product.
- Caution in patients at risk of kidney problems, including the elderly or those using diuretics.
- Stop use immediately if you have difficulty or pain when urinating.
- Talk to your doctor if you are trying to conceive, in your first or second trimester of pregnancy or if breastfeeding.

#### **What is MOTRIN® LIQUID GELS 400 mg used for?**

MOTRIN® Liquid Gels 400 mg provides fast and effective relief of pain from:

- muscle aches and pain, joint and body pain, backache, muscle sprains and strains,
- pain of inflammation associated with conditions including:
  - arthritis,
  - physical or athletic overexertion (e.g. sprains or strains),
- headache including tension headache,
- dental pain,
- menstrual pain,
- aches and pain due to the common cold and flu.

Temporary relief of mild to moderate migraine headaches including associated symptoms of nausea, and sensitivity to light and sound.

Clinical studies show long lasting pain relief up to 8 hours.

Reduction of fever.

### **How does MOTRIN® LIQUID GELS 400 mg work?**

MOTRIN® (ibuprofen) Liquid Gels 400 mg starts to work fast and treats pain where it starts. Ibuprofen is a member of a class of drugs called non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs work within the body by blocking the production of substances, called prostaglandins, which are involved in the development of pain and inflammation.

### **What are the ingredients in MOTRIN® LIQUID GELS 400 mg?**

Medicinal ingredients: Ibuprofen (free acid and potassium salt).

Non-medicinal ingredients: gelatin, pharmaceutical ink, polyethylene glycol, potassium hydroxide, propylene glycol, purified water and sorbitol.

### **MOTRIN® LIQUID GELS 400 mg comes in the following dosage forms:**

Capsules, 400 mg

### **Do not use MOTRIN® LIQUID GELS 400 mg if:**

- You are:
  - taking acetylsalicylic acid (ASA) or any other non-steroidal anti-inflammatory medication including any other ibuprofen product.
  - allergic or have had a reaction to ibuprofen, acetylsalicylic acid (ASA), other non-steroidal anti-inflammatory drugs (NSAIDs) or salicylates, or to any ingredient in the formulation (see Non-medicinal ingredients above). Allergic reactions may appear as hives, difficulty breathing, shock, skin reddening, rash or blisters, swelling of the face or throat, or sudden collapse.
  - dehydrated (significant fluid loss) due to vomiting, diarrhea or lack of fluid intake.
  - in your third trimester of pregnancy.
  
- You have:
  - nasal polyps (growth inside your nose), or allergic manifestations such as asthma, anaphylaxis (sudden severe life-threatening anaphylactic reactions), urticaria/hives, rhinitis (stuffed or runny nose that may be due to allergies), skin rash or other allergic symptoms.

- active or recurrent stomach ulcer, gastrointestinal (GI) bleeding, or active inflammatory bowel disease (e.g. Crohn's, colitis).
  - serious liver or kidney disease.
  - systemic lupus erythematosus.
  - high potassium in the blood.
- You recently had or are about to have heart surgery.

**To help avoid side effects and ensure proper use, talk to your healthcare professional before you take MOTRIN® LIQUID GELS 400 mg. Talk about any health conditions or problems you may have, including if you:**

- have previous or current stomach ulcers, high blood pressure, asthma, heart failure, heart disease or thyroid disease, kidney or liver disease, glaucoma, diabetes, alcoholism, a history of stomach bleeding, or any other serious disease or condition.
- are taking any drug including over the counter drugs.
- are pregnant or breastfeeding
- have a blood-clotting disorder (e.g. hemophilia, sickle cell anemia, etc.).
- are on a special diet (e.g. low-sodium).

**Other warnings you should know about:**

- Use with caution in the elderly.
- Long-term continuous use may increase the risk of heart attack or stroke.
- The use of NSAIDs, like MOTRIN® LIQUID GELS 400 mg, in the second trimester of pregnancy should be restricted to the lowest dose necessary for shortest possible duration.
- At 20 weeks or later in pregnancy, your use of NSAIDs may need to be monitored by a doctor due to the rare risk of kidney problems in the unborn baby which may result in decreased amniotic fluid volume and other complications.

**Stop use and ask a doctor if**

- you show signs of stomach bleeding
- pain worsens or lasts more than 5 days
- fever worsens or lasts more than 3 days
- any new symptoms appear

**Driving and using machines:** If you become drowsy, dizzy or lightheaded, do not drive or operate machinery and contact your doctor or pharmacist.

**Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.**

**The following may interact with MOTRIN® LIQUID GELS 400 mg:**

- acetaminophen
- anticoagulants (blood thinners)
- ASA or other NSAIDs
- digoxin
- diuretics (water pills)
- lithium
- medications for high blood pressure
- methotrexate
- oral antidiabetic agents and insulin
- protein-bound drugs including probenecid, thyroxine, antibiotics, cyclosporine, phenytoin, corticosteroids or benzodiazepines
- selective serotonin reuptake inhibitors (medicine used to treat depression)

Do not use MOTRIN® Liquid Gels 400 mg if you are taking daily low dose ASA (81 – 325 mg), without talking to a doctor or pharmacist. Ibuprofen may interfere with the preventive benefits of ASA.

**How to take MOTRIN® LIQUID GELS 400 mg:**

Stomach upset is one of the common problems with NSAIDs. To lessen stomach upset, take this medicine immediately after a meal or with food or milk. If stomach upset (indigestion, nausea, vomiting, stomach pain or diarrhoea) occurs and continues, contact your doctor.

Do not give to children under 12. Children's MOTRIN® formulations are available to treat children under 12 years of age.

**Usual dose:**

For migraine headaches: Adults and children over 12: Take 1 capsule at the first sign of symptoms and every 6-8 hours as needed. Do not exceed 3 capsules in 24 hours, unless directed by a doctor.

For all other uses: Adults and children over 12: Take 1 capsule every 6-8 hours as needed. Do not exceed 3 capsules in 24 hours, unless directed by a doctor.

Use the lowest effective dose for the shortest duration.

**Overdose:**

If you think you, or a person you are caring for, have taken too much MOTRIN® LIQUID GELS 400 mg, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

**Missed Dose:**

If a dose is missed, resume dosing on the normal schedule without exceeding the maximum allowed for 24 hours.

**What are possible side effects from using MOTRIN® LIQUID GELS 400 mg?**

These are not all the possible side effects you may have when taking MOTRIN® LIQUID GELS 400 mg. If you experience any side effects not listed here, tell your healthcare professional.

Along with its needed effects, MOTRIN® Liquid Gels 400 mg like other NSAIDs may cause some unwanted effects especially when used for a long time or in large doses. However, at the maximum daily dose of 1200 mg, there are very few side effects seen and these are primarily only gastrointestinal.

The most common side effects with this medication are indigestion, nausea, vomiting, heartburn, dizziness, and skin rashes.

The other side effects, which might be seen, are sudden abdominal pain or long-term abdominal pain with the loss of appetite and/or jaundice and/or new onset of itching, diarrhoea, flatulence, constipation, abdominal cramp, headache, nervousness, drowsiness, itching, decreased appetite, sleeplessness and fluid retention.

If unusual symptoms or any of the following reactions develop during treatment, stop use and see a doctor immediately.

<b>Serious side effects and what to do about them</b>			
<b>Symptom / effect</b>	<b>Talk to your healthcare professional</b>		<b>Stop taking drug and get immediate medical help</b>
	<b>Only if severe</b>	<b>In all cases</b>	
<b>UNCOMMON</b>			
Chills, fever, muscle aches or pains, or other flu-like symptoms shortly before or together with a skin rash		√	
Bloody or black tarry stools		√	
Hives or itching, skin reddening, blisters		√	
Blurred vision		√	
Swelling of feet or lower legs		√	



<b>Serious side effects and what to do about them</b>			
<b>Symptom / effect</b>	<b>Talk to your healthcare professional</b>		<b>Stop taking drug and get immediate medical help</b>
	<b>Only if severe</b>	<b>In all cases</b>	
Hearing problems (ringing or buzzing in the ears)		√	
Mental confusion or depression		√	
Shortness of breath, chest pain, trouble breathing, asthma, sinusitis (nasal congestion), wheezing, or tightness in the chest		√	
Vomiting blood		√	
Yellow discoloration of the skin or eyes, with or without fatigue		√	
Any changes in the amount or colour of your urine (such as dark; red or brown), any pain or difficulty experienced in urination, loss of appetite, dizziness, or light headedness		√	
Stomach pain	√		
Heart Failure			√

In addition to checking with your doctor, if these serious side effects occur, stop taking this medication.

Side effects may be minimized by using the smallest dose for the shortest duration of time.

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

### **Reporting Side Effects**

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

### **Storage:**

Store at 15 - 30°C. Protect from heat and humidity.

Keep out of reach and sight of children. This package contains enough medicine to seriously harm a child.

Do not keep outdated medicine or medicine no longer needed.

### **If you want more information about MOTRIN® LIQUID GELS 400 mg:**

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website [www.motrin.ca](http://www.motrin.ca), or by calling 1-800-6 MOTRIN / 1-888-666-8746.

This leaflet was prepared by McNeil Consumer Healthcare, division of Johnson & Johnson Inc.,

Last Revised: April 5, 2023